REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
26/01/2026
Voltar para busca
Dado oficial do USPTO
ACTICOR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
27/01/2026
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
05/07/2019
Data de registro
26/01/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/01/2021
Última transação
27/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
34
Localização do titular
FR
Examinador
CIANCI, RYAN MICHAEL
Unidade examinadora
M70
Localização atual
TMO LAW OFFICE 116
Titulares e representantes
Titulares
A. B. (pessoa física)
Representantes
Pina M. Campagna Carter, DeLuca, & Farrell, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Monoclonal antibodies for scientific use; reagents for scientific or medical research use; biochemicals for in vitro and in vivo scientific use and medical research use; biological preparations * of monoclonal antibodies * for use in industry and science ; proteins in raw material form for use in scientific research
Classe 5
Antibodies in the form of biological preparations for the prevention and treatment of arterial and venous thrombosisrestenosisthromboembolic diseases; pharmaceuticals for prevention and treatment of arterial and venous thrombosisrestenosisthromboembolic diseases; pharmaceutical preparations and substances prevention and treatment of arterial and venous thrombosisrestenosisthromboembolic diseases
Classe 42
Medical and scientific laboratory services relating to the production of antibodies; biotechnological and pharmaceutical drug development services; pharmaceutical and biotechnological research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development in the pharmaceutical and biotechnology fields
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/05/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
28/04/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
28/04/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/04/2021
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
28/01/2021
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
28/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
26/01/2021
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
17/12/2020
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
11/12/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
09/07/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/06/2020
PUBO
PUBLISHED FOR OPPOSITION
09/06/2020
GPNX
NOTIFICATION PROCESSED BY IB
05/06/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/05/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
20/05/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/05/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/05/2020
ALIE
ASSIGNED TO LIE
04/05/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/04/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
27/04/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/04/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
27/04/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/04/2020
RFNT
REFUSAL PROCESSED BY IB
02/11/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/10/2019
RFRR
REFUSAL PROCESSED BY MPU
17/10/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/10/2019
CNRT
NON-FINAL ACTION WRITTEN
01/10/2019
DOCK
ASSIGNED TO EXAMINER
23/09/2019
MAFR
APPLICATION FILING RECEIPT MAILED
04/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
31/08/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
22/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ACTICOR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.